According to the Zhitong Finance App, Fosun Pharmaceutical (02196) announced the results for the first three quarters of 2026. The group obtained operating revenue of RMB 30.463 billion, an increase of 3.64% over the previous year; net profit attributable to shareholders of listed companies was RMB 2,667 billion, an increase of 5.71% over the previous year; and basic earnings per share were 1.01 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.